This study investigates advanced PALB2 pancreatic cancer. Participants in this study have previously undergone treatment for their condition.
The study evaluates the safety and effectiveness of an investigational medication for individuals with this specific type of pancreatic cancer.
- Who can participate: Adults aged 18 and older with a PALB2 gene mutation and advanced pancreatic cancer may be eligible. Participants must have received at least one prior treatment for advanced disease.
- Study details: Participants will take the investigational medication twice daily. The study will continue until certain conditions are met, such as disease progression or unacceptable side effects.